Credit Suisse Ag Aptinyx Inc. Transaction History

Credit Suisse Ag

  • $101 Billion
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021
SELL
$2.86 - $4.33 $32,126 - $48,638
-11,233 Closed
0 $0
Q4 2020

Feb 12, 2021
BUY
$2.93 - $4.3 $32,912 - $48,301
11,233 New
11,233 $39,000

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email